Online inquiry

IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6431MR)

This product GTTS-WQ6431MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets HA gene. The antibody can be applied in Influenza A infection research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_308669.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3654620
UniProt ID Q9Q0U6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ6431MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1465MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ142MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ7119MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA FE 999302
GTTS-WQ13812MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-10987
GTTS-WQ13581MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA QAX-576
GTTS-WQ7928MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GSK3196165
GTTS-WQ8199MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA hLIV22
GTTS-WQ6189MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CP-870893
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW